<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US4978680 - Treating patients with 2-phenyl 1,3-propanediol dicarbamate - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Treating patients with 2-phenyl 1,3-propanediol dicarbamate"><meta name="DC.contributor" content="Robert D. Sofia" scheme="inventor"><meta name="DC.contributor" content="Carter-Wallace, Inc." scheme="assignee"><meta name="DC.date" content="1989-9-26" scheme="dateSubmitted"><meta name="DC.description" content="A novel method for the prevention and control of epileptic seizures employing pharmaceutical compositions containing 2-phenyl-1,3-propanediol dicarbamate."><meta name="DC.date" content="1990-12-18" scheme="issued"><meta name="citation_reference" content="Chem Abst. 104 180056v (1986)."><meta name="citation_reference" content="Chem-Abst. 104-180056v (1986)."><meta name="citation_patent_number" content="US:4978680"><meta name="citation_patent_application_number" content="US:07/412,964"><link rel="canonical" href="http://www.google.com/patents/US4978680"/><meta property="og:url" content="http://www.google.com/patents/US4978680"/><meta name="title" content="Patent US4978680 - Treating patients with 2-phenyl 1,3-propanediol dicarbamate"/><meta name="description" content="A novel method for the prevention and control of epileptic seizures employing pharmaceutical compositions containing 2-phenyl-1,3-propanediol dicarbamate."/><meta property="og:title" content="Patent US4978680 - Treating patients with 2-phenyl 1,3-propanediol dicarbamate"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("sKntU_y2BKXKsQSHpYLoCQ"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("NOR"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("sKntU_y2BKXKsQSHpYLoCQ"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("NOR"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us4978680?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US4978680"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=4-IuBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS4978680&amp;usg=AFQjCNHGGeUlQgltjfb1vqmFkFuuE_pkhQ" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US4978680.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US4978680.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US4978680" style="display:none"><span itemprop="description">A novel method for the prevention and control of epileptic seizures employing pharmaceutical compositions containing 2-phenyl-1,3-propanediol dicarbamate....</span><span itemprop="url">http://www.google.com/patents/US4978680?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US4978680 - Treating patients with 2-phenyl 1,3-propanediol dicarbamate</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US4978680 - Treating patients with 2-phenyl 1,3-propanediol dicarbamate" title="Patent US4978680 - Treating patients with 2-phenyl 1,3-propanediol dicarbamate"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US4978680 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 07/412,964</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Dec 18, 1990</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Sep 26, 1989</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Sep 26, 1989</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/DE69028542D1">DE69028542D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69028542T2">DE69028542T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0491094A1">EP0491094A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0491094B1">EP0491094B1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">07412964, </span><span class="patent-bibdata-value">412964, </span><span class="patent-bibdata-value">US 4978680 A, </span><span class="patent-bibdata-value">US 4978680A, </span><span class="patent-bibdata-value">US-A-4978680, </span><span class="patent-bibdata-value">US4978680 A, </span><span class="patent-bibdata-value">US4978680A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Robert+D.+Sofia%22">Robert D. Sofia</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Carter-Wallace,+Inc.%22">Carter-Wallace, Inc.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US4978680.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US4978680.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US4978680.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (2),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (31),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (5),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (14)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=4-IuBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/4978680&usg=AFQjCNFjzy4g4CKpRRJuTXqL7iJ7qhCJjg">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=4-IuBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D4978680&usg=AFQjCNGcrgZ4gCt2YnderSvYhOTfWL4WpQ">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=4-IuBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D4978680A%26KC%3DA%26FT%3DD&usg=AFQjCNFXxjCTY8xGhmYHIiwoUBT5t1eKjw">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT129474354" lang="EN" load-source="ifi">Treating patients with 2-phenyl 1,3-propanediol dicarbamate</invention-title></span><br><span class="patent-number">US 4978680 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA36988853" lang="EN" load-source="patent-office"> <div class="abstract">A novel method for the prevention and control of epileptic seizures employing pharmaceutical compositions containing 2-phenyl-1,3-propanediol dicarbamate.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(5)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4978680-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4978680-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4978680-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4978680-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4978680-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4978680-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4978680-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4978680-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4978680-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4978680-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(1)</span></span></div><div class="patent-text"><div mxw-id="PCLM4372050" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A method for reducing the incidence and severity of epileptic seizures which comprises administering to a warm-blooded animal in need of such treatment a therapeutic amount of 2-phenyl-1,3-propanediol dicarbamate.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES66035667" lang="EN" load-source="patent-office" class="description">
    <p>The present invention relates to pharmaceutical compositions containing 2-phenyl-1,3-propanediol dicarbamate as an active component and to methods for the prevention and control of epileptic seizures by the use of such compositions</p>
    <p>More particularly, the present invention further relates to methods for increasing epileptic seizure threshold and the prevention of epileptic seizure spread through the administration of therapeutic compositions which contain as an active ingredient 2-phenyl-1,3-propanediol dicarbamate commonly known as Felbamate.</p>
    <p>Felbamate is a well known pharmaceutical compound having been described in U.S. Pat. Nos. 2,884,444 and 4,868,327.</p>
    <p>Epilepsy, a disease which has been characterized as a paroxysmal, self-sustaining and self-limited cerebral dysrhythmia, genetic or acquired in origin and physiologic or organic in mechanism is generallY divided into four main types based on the type of seizure that occurs in those afflicted with the disease.</p>
    <p>Based on clinical and electroencephalographic observations, the four general subdivisions of epilepsy are:</p>
    <p>1. Grand mal</p>
    <p>2. Petit mal</p>
    <p>3. Psychomotor</p>
    <p>4. Autonomic</p>
    <p>Those afflicted with epilepsy may present with any one of or a mixture of the foregoing forms of the disease.</p>
    <p>In theory, it is believed that anti-epileptic drugs act to prevent or control seizures by acting on the seizure focus which may be a collection of pathologically altered neurons or normal cells having restricted vascular supply or an injured area in which the neurons of a nerve net have been destroyed.</p>
    <p>Up to the present time, all drugs used in the treatment of epilepsy function as prophylactics against the symptoms of epilepsy, i.e., the reduction and control of epileptic seizures as opposed to being curatives.</p>
    <p>Although it is generally recognized that approximately 50% of epileptic patients can be controlled with presently available anti-epileptic medications, there is a continuing long felt need for more selective and less toxic anti-epileptic drugs. The desiratum of the art has been to provide a non-toxic, non-sedative, long-acting and highly effective anti-epileptic drugs.</p>
    <p>Phenytoin and carbamazepine are presently the drugs of choice for control of both generalized tonic-clonic (grand mal) and complex partial (temporal lobe) epileptic seizures.</p>
    <p>In addition to gingival hyperplasia and hirsutism peculiar to phenytoin, both drugs have been reported to induce cerebellar-vestibular effects, skin disorders, hepatic deficiencies and congenital abnormalities. The foregoing toxicity profile for both phenytoin and carbamazepine clearly demonstrates a need for less toxic substances for use as anti-epileptic medications.</p>
    <p>One of the objects of the present invention is to provide compositions for the treatment of epilepsy comprising felbamate as the active ingredient.</p>
    <p>Another object of the present invention is to provide relatively non-toxic compositions effective to control or prevent epileptic seizures which have a unique spectrum of anti-epileptic activity and which include felbamate as an active component.</p>
    <p>A further object of the present invention is to provide compositions for the prevention and control of epileptic seizures which compositions are relatively non-toxic, have a high degree of effectiveness and continue to produce a therapeutic response over relatively long periods of time.</p>
    <p>Moreover, it is an object of the present invention to provide methods for the prevention and control of epileptic seizures through the use of felbamate.</p>
    <p>Accordingly, it has been found that felbamate chemically described as 2-phenyl-1,3-propanediol dicarbamate is a compound which has demonstrated superior properties when compared to prototype drugs, i.e., phenytoin with respect to increasing seizure threshold and prevention seizure spread.</p>
    <p>The compositions for the treatment of epilepsy may take any of a variety of forms although theY are intended primarily for oral use and is suitable for forming into pills, capsules and tablets by well-known practices. When the active ingredient is in the form of a solid, a typical tablet composition comprises 500 milligrams of 2-phenyl-1,3-propanediol dicarbamate intermixed in a dry pulverulent state with suitable solid carriers and diluents.</p>
    <p>In general, an effective daily dose of the active ingredient is in the range of from about 100 milligrams to about 5 grams.</p>
    <p>Solid carriers and diluents suitable for use include sugars such as lactose and sucrose; cellulose derivatives such as carboxymethyl cellulose, ethyl cellulose, methyl cellulose, etc., gelatin including hard and soft gelatin capsules, talc, cornstarch, stearic acid and magnesium stearate.</p>
    <p>The percentage of 2-phenyl-1,3-propanediol dicarbamate in the compositions may be varied over wide limits and the quantity of medicament furnished by each individual tablet or capsule is relatively unimportant since the indicated total daily dose can be reached by administering either one or a plurality of capsules or tablets. However, for convenience in manufacturing and ease of administration, it is preferable that each dosage form contains at least 25 milligrams and up to 500  milligrams of 2-phenyl-1,3-propanediol dicarbamate per unit dosage form.</p>
    <heading>EXAMPLE 1</heading> <p>2-phenyl-1,3-propanediol dicarbamate is constituted into 500 mg. dosage units by encapsulation without an adjuvant into hard gelatin capsules The yield from 1000 g. of 2-phenyl-1,3-propanediol dicarbamate is about 2000 capsules each containing 500 mg. of medicant.</p>
    <heading>EXAMPLE 2</heading> <p>A tableting formulation is prepared as follows:</p>
    <p>83 g. 2-phenyl-1,3-propanediol dicarbamate</p>
    <p>13 g. powdered sugar with 3% starch</p>
    <p>76 g. corn syrup</p>
    <p>q.s. water</p>
    <p>13 g. talc U.S.P. powdered Italian</p>
    <p>3 g. magnesium stearate</p>
    <p>q.s alcohol</p>
    <p>flavoring</p>
    <p>The formulation is compressed into tablets, each containing 200 mg. of 2-phenyl-1,3-propanediol dicarbamate. The yield is about 1750 tablets.</p>
    <p>Felbamate (2-phenyl-1,3-propanediol dicarbamate) has a very favorable preclinical profile characterized by a substantial margin of safety (protective index 16.9-19.1). The following example presents the results from a double-blind randomized clinical trial in patients with partial seizures. Criteria for patient entry into the study were 4 or more complex partial seizures per month in spite of treatment with both phenytoin and carbamazepine.</p>
    <heading>EXAMPLE 3</heading> <p>Fifty-six patients (mean age 31.4 years; male=32, female=24) completed the study. The mean seizure frequencies for the eight week periods analyzed were: baseline=39.8;  felbamate=34.9; placebo=40.2. Felbamate was significantly superior to placebo by percent seizure reduction (P=0.018) and truncated percent seizure reduction (p=0.007).</p>
    <p>The mean felbamate dose was 2300 mg/day. Plasma felbamate concentrations ranged from 18.4 to 51.9, mean=32.5 mg/ml.</p>
    <p>Adverse effects were minor and consisted of nausea and CNS effects.</p>
    <p>The superiority of felbamate over placebo in a population of persons with severely refractory epilepsy indicates this medication to be a major anti-epileptic agent.</p>
    <p>It should be understood that the above examples are illustrative of the best mode only of the invention herein disclosed. Given the present disclosure, it is anticipated that numerous variations will occur to those skilled in the art. A latitude of modification, substitution and change is intended and in some instances, some features of the invention will be employed without a corresponding use of other features. Accordingly, it is intended that the spirit and scope of the invention disclosed herein should be limited only by the following claims.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Chem Abst. 104 180056v (1986).</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chem-Abst. 104-180056v (1986).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5290808">US5290808</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 6, 1992</td><td class="patent-data-table-td patent-date-value">Mar 1, 1994</td><td class="patent-data-table-td ">Carter-Wallace, Inc.</td><td class="patent-data-table-td ">Method to control the intake of food</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5462966">US5462966</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 15, 1993</td><td class="patent-data-table-td patent-date-value">Oct 31, 1995</td><td class="patent-data-table-td ">Carter-Wallace Inc.</td><td class="patent-data-table-td ">Methods for the prevention and control of cellular damage resulting from coronary artery occlusion-reperfusion</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5492930">US5492930</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 25, 1994</td><td class="patent-data-table-td patent-date-value">Feb 20, 1996</td><td class="patent-data-table-td ">Schering Corporation</td><td class="patent-data-table-td ">Administering 2-phenyl-1,3-propanediol monocarbamate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5728728">US5728728</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 10, 1996</td><td class="patent-data-table-td patent-date-value">Mar 17, 1998</td><td class="patent-data-table-td ">Kozachuk; Walter E.</td><td class="patent-data-table-td ">Administering felbamate to human having sepsis, hiv dementia, meningitis or central nervous system vasculitis, which is a neuronal cell protecting antagonist of glycine site of n-methyl-d-aspartate receptor complex</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6515019">US6515019</a></td><td class="patent-data-table-td patent-date-value">Mar 6, 2001</td><td class="patent-data-table-td patent-date-value">Feb 4, 2003</td><td class="patent-data-table-td ">Walter E. Kozachuk</td><td class="patent-data-table-td ">Methods of providing symptomatic and prophylactic treatment for medical and neurological conditions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6538024">US6538024</a></td><td class="patent-data-table-td patent-date-value">Aug 9, 2001</td><td class="patent-data-table-td patent-date-value">Mar 25, 2003</td><td class="patent-data-table-td ">University Of Virginia Patent Foundation</td><td class="patent-data-table-td ">Felbamate derived compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6599935">US6599935</a></td><td class="patent-data-table-td patent-date-value">Dec 17, 2001</td><td class="patent-data-table-td patent-date-value">Jul 29, 2003</td><td class="patent-data-table-td ">University Of Virginia Patent Foundation</td><td class="patent-data-table-td ">2-phenyl-1,3-propanediol dicarbamate derivatives used as antiepileptic and antiischemic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6759402">US6759402</a></td><td class="patent-data-table-td patent-date-value">Jun 6, 2003</td><td class="patent-data-table-td patent-date-value">Jul 6, 2004</td><td class="patent-data-table-td ">University Of Virginia Patent Foundation</td><td class="patent-data-table-td ">Cyclic felbamate derived compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7209787">US7209787</a></td><td class="patent-data-table-td patent-date-value">Nov 20, 2003</td><td class="patent-data-table-td patent-date-value">Apr 24, 2007</td><td class="patent-data-table-td ">Bioneuronics Corporation</td><td class="patent-data-table-td ">Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7231254">US7231254</a></td><td class="patent-data-table-td patent-date-value">Jul 12, 2004</td><td class="patent-data-table-td patent-date-value">Jun 12, 2007</td><td class="patent-data-table-td ">Bioneuronics Corporation</td><td class="patent-data-table-td ">Closed-loop feedback-driven neuromodulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7242984">US7242984</a></td><td class="patent-data-table-td patent-date-value">Jan 6, 2004</td><td class="patent-data-table-td patent-date-value">Jul 10, 2007</td><td class="patent-data-table-td ">Neurovista Corporation</td><td class="patent-data-table-td ">Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7277758">US7277758</a></td><td class="patent-data-table-td patent-date-value">Apr 5, 2004</td><td class="patent-data-table-td patent-date-value">Oct 2, 2007</td><td class="patent-data-table-td ">Neurovista Corporation</td><td class="patent-data-table-td ">Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7324851">US7324851</a></td><td class="patent-data-table-td patent-date-value">Jun 1, 2004</td><td class="patent-data-table-td patent-date-value">Jan 29, 2008</td><td class="patent-data-table-td ">Neurovista Corporation</td><td class="patent-data-table-td ">Closed-loop feedback-driven neuromodulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7403820">US7403820</a></td><td class="patent-data-table-td patent-date-value">May 25, 2005</td><td class="patent-data-table-td patent-date-value">Jul 22, 2008</td><td class="patent-data-table-td ">Neurovista Corporation</td><td class="patent-data-table-td ">Closed-loop feedback-driven neuromodulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7623928">US7623928</a></td><td class="patent-data-table-td patent-date-value">May 2, 2007</td><td class="patent-data-table-td patent-date-value">Nov 24, 2009</td><td class="patent-data-table-td ">Neurovista Corporation</td><td class="patent-data-table-td ">Controlling a subject&#39;s susceptibility to a seizure</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7676263">US7676263</a></td><td class="patent-data-table-td patent-date-value">Jun 21, 2007</td><td class="patent-data-table-td patent-date-value">Mar 9, 2010</td><td class="patent-data-table-td ">Neurovista Corporation</td><td class="patent-data-table-td ">Minimally invasive system for selecting patient-specific therapy parameters</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7747325">US7747325</a></td><td class="patent-data-table-td patent-date-value">Sep 28, 2005</td><td class="patent-data-table-td patent-date-value">Jun 29, 2010</td><td class="patent-data-table-td ">Neurovista Corporation</td><td class="patent-data-table-td ">Systems and methods for monitoring a patient&#39;s neurological disease state</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7853329">US7853329</a></td><td class="patent-data-table-td patent-date-value">Dec 29, 2006</td><td class="patent-data-table-td patent-date-value">Dec 14, 2010</td><td class="patent-data-table-td ">Neurovista Corporation</td><td class="patent-data-table-td ">Monitoring efficacy of neural modulation therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7884227">US7884227</a></td><td class="patent-data-table-td patent-date-value">Oct 27, 2008</td><td class="patent-data-table-td patent-date-value">Feb 8, 2011</td><td class="patent-data-table-td ">Navinta Llc</td><td class="patent-data-table-td ">Felbamate with improved bulk density</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7930035">US7930035</a></td><td class="patent-data-table-td patent-date-value">May 2, 2007</td><td class="patent-data-table-td patent-date-value">Apr 19, 2011</td><td class="patent-data-table-td ">Neurovista Corporation</td><td class="patent-data-table-td ">Providing output indicative of subject&#39;s disease state</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8036736">US8036736</a></td><td class="patent-data-table-td patent-date-value">Mar 21, 2008</td><td class="patent-data-table-td patent-date-value">Oct 11, 2011</td><td class="patent-data-table-td ">Neuro Vista Corporation</td><td class="patent-data-table-td ">Implantable systems and methods for identifying a contra-ictal condition in a subject</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8295934">US8295934</a></td><td class="patent-data-table-td patent-date-value">Nov 14, 2006</td><td class="patent-data-table-td patent-date-value">Oct 23, 2012</td><td class="patent-data-table-td ">Neurovista Corporation</td><td class="patent-data-table-td ">Systems and methods of reducing artifact in neurological stimulation systems</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8543199">US8543199</a></td><td class="patent-data-table-td patent-date-value">Sep 2, 2011</td><td class="patent-data-table-td patent-date-value">Sep 24, 2013</td><td class="patent-data-table-td ">Cyberonics, Inc.</td><td class="patent-data-table-td ">Implantable systems and methods for identifying a contra-ictal condition in a subject</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8588933">US8588933</a></td><td class="patent-data-table-td patent-date-value">Jan 11, 2010</td><td class="patent-data-table-td patent-date-value">Nov 19, 2013</td><td class="patent-data-table-td ">Cyberonics, Inc.</td><td class="patent-data-table-td ">Medical lead termination sleeve for implantable medical devices</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8725243">US8725243</a></td><td class="patent-data-table-td patent-date-value">Dec 28, 2005</td><td class="patent-data-table-td patent-date-value">May 13, 2014</td><td class="patent-data-table-td ">Cyberonics, Inc.</td><td class="patent-data-table-td ">Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8762065">US8762065</a></td><td class="patent-data-table-td patent-date-value">Jun 22, 2005</td><td class="patent-data-table-td patent-date-value">Jun 24, 2014</td><td class="patent-data-table-td ">Cyberonics, Inc.</td><td class="patent-data-table-td ">Closed-loop feedback-driven neuromodulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8781597">US8781597</a></td><td class="patent-data-table-td patent-date-value">May 5, 2010</td><td class="patent-data-table-td patent-date-value">Jul 15, 2014</td><td class="patent-data-table-td ">Cyberonics, Inc.</td><td class="patent-data-table-td ">Systems for monitoring a patient&#39;s neurological disease state</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8786624">US8786624</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 2010</td><td class="patent-data-table-td patent-date-value">Jul 22, 2014</td><td class="patent-data-table-td ">Cyberonics, Inc.</td><td class="patent-data-table-td ">Processing for multi-channel signals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0514598A1?cl=en">EP0514598A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 22, 1991</td><td class="patent-data-table-td patent-date-value">Nov 25, 1992</td><td class="patent-data-table-td ">Carter-Wallace, Inc.</td><td class="patent-data-table-td ">Use of felbamate in a medicament for the treatment of hypoxic damage</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0531105A1?cl=en">EP0531105A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 2, 1992</td><td class="patent-data-table-td patent-date-value">Mar 10, 1993</td><td class="patent-data-table-td ">Carter-Wallace, Inc.</td><td class="patent-data-table-td ">Use of felbamate for the manufacture of a medicament for the treatment of neuropsychopharmacological disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1997037652A1?cl=en">WO1997037652A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 10, 1997</td><td class="patent-data-table-td patent-date-value">Oct 16, 1997</td><td class="patent-data-table-td ">Walter E Kozachuk</td><td class="patent-data-table-td ">Methods of providing neuroprotection</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=4-IuBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S534000">514/534</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=4-IuBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S541000">514/541</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=4-IuBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031270000">A61K31/27</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=4-IuBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/27">A61K31/27</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K31/27</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Dec 9, 2008</td><td class="patent-data-table-td ">FPB1</td><td class="patent-data-table-td ">Expired due to reexamination which canceled all claims</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 31, 2006</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20060330</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 6, 2006</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">GENERAL ELECTRIC CAPITAL CORPORATION, MARYLAND</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:MEDPOINTE HEALTHCARE INC.;REEL/FRAME:017730/0008</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20060524</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 25, 2006</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MEDPOINTE HEALTHCARE INC., NEW JERSEY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">RELEASE BY SECURED PARTY;ASSIGNOR:LEHMAN COMMERICAL PAPER INC.;REEL/FRAME:017675/0384</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20060524</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 16, 2006</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MEDPOINTE HEALTHCARE INC., NEW JERSEY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOFIA, ROBERT D.;REEL/FRAME:017619/0803</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20060428</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 12, 2005</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MEDPOINTE HEALTHCARE INC., NEW JERSEY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:CARTER-WALLACE, INC.;REEL/FRAME:016245/0386</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20011001</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 9, 2002</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 9, 2002</td><td class="patent-data-table-td ">SULP</td><td class="patent-data-table-td ">Surcharge for late payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">11</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 2, 2002</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 24, 2001</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">LEHMAN COMMERCIAL PAPER INC., NEW JERSEY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNORS:MEDPOINT INC.;MCC ACQUISITION SUB CORPORATION;MCC MERGER SUB CORPORATION;REEL/FRAME:012530/0854</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20010928</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">LEHMAN COMMERCIAL PAPER INC. 101 HUDSON STREET, 31</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNORS:MEDPOINT INC. /AR;REEL/FRAME:012530/0854</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 4, 1998</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 10, 1994</td><td class="patent-data-table-td ">SULP</td><td class="patent-data-table-td ">Surcharge for late payment</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 10, 1994</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 26, 1994</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U0CQ5fiSus9R7vS7m3hSPuzIoF14g\u0026id=4-IuBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U2Eu9muQKQ1RzaqtLMkx8e808J0yw\u0026id=4-IuBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U3uFhsPr8AUlbucrW2WxZIDX_TEjA","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Treating_patients_with_2_phenyl_1_3_prop.pdf?id=4-IuBAABERAJ\u0026output=pdf\u0026sig=ACfU3U12Mhv3X15FY3TJ8hvT5GId3QBEdA"},"sample_url":"http://www.google.com/patents/reader?id=4-IuBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>